Drug Details

General Information of the Drug (ID: DR6052)
Name
Halofuginone
Synonyms
7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one; empostatin; 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one.; Halofuginone (INN); Halocur [veterinary] (TN); SCHEMBL25596; CHEMBL1199539; DTXSID0048260; BCBcMAP01_000063; BCBcMAP01_000107; AMY39119; HY-N1584; ZINC1849659; AKOS026669540; CS-5485; SB19686; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; NCI60_039464; D08034; 837H202; A830836; Q-201182; UNII-L31MM1385E component LVASCWIMLIKXLA-LSDHHAIUSA-N; 7-Bromo-6-chloro-3-[3-(3alpha-hydroxypiperidin-2beta-yl)-2-oxopropyl]quinazolin-4(3H)-one; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4-quinazolinone; 7-bromanyl-6-chloranyl-3-[2-oxidanylidene-3-[(2S,3R)-3-oxidanylpiperidin-2-yl]propyl]quinazolin-4-one; 7695-84-3
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C16H17BrClN3O3
PubChem CID
400772
Canonical SMILES
C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
InChI
1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m0/s1
InChIKey
LVASCWIMLIKXLA-LSDHHAIUSA-N
CAS Number
CAS 55837-20-2
DrugBank ID
DB04866
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Artemisinin      Artemisia annua     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CDKN1A  Molecule Info 
Pathway MAP
Up-regulation Expression CDKN1B  Molecule Info 
Pathway MAP
                    In-vitro Model HCT 116 CVCL_0291 Colon carcinoma Homo sapiens
SW480 CVCL_0546 Colon adenocarcinoma Homo sapiens
SW620 CVCL_0547 Colon adenocarcinoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
A-375 CVCL_0132 Amelanotic melanoma Homo sapiens
MGC-803 CVCL_5334 Gastric mucinous adenocarcinoma Homo sapiens
Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
Hep 3B2.1-7 CVCL_0326 Childhood hepatocellular carcinoma Homo sapiens
                    In-vivo Model HCT116 cells (5*106 cells per mouse) were suspended in PBS and inoculated subcutaneously into the left flank of each female BALB/c nude mice.
                    Experimental
                    Result(s)		 Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.
Target and Pathway
Target(s) GCSF receptor (G-CSF-R)  Molecule Info  [3]
KEGG Pathway Cytokine-cytokine receptor interaction Click to Show/Hide
2 PI3K-Akt signaling pathway
3 Jak-STAT signaling pathway
4 Hematopoietic cell lineage
5 Pathways in cancer
NetPath Pathway Leptin Signaling Pathway Click to Show/Hide
2 RANKL Signaling Pathway
References
Reference 1 ClinicalTrials.gov (NCT00027677) Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
Reference 2 Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. Oncotarget. 2016 Aug 2;7(31):50302-50314.
Reference 3 Granulocyte colony-stimulating factor. South Med J. 1993 Mar;86(3):350-5.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link